Standout Papers

Atogepant for the Preventive Treatment of Migraine 2021 2026 2022 2024176
  1. Atogepant for the Preventive Treatment of Migraine (2021)
    Jessica Ailani, Richard B. Lipton et al. New England Journal of Medicine
  2. Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial (2023)
    Patricia Pozo‐Rosich, Jessica Ailani et al. The Lancet

Citation Impact

60 standout
Sub-graph 1 of 22

Citing Papers

Diagnosis and management of subarachnoid haemorrhage
2024 Standout
Conducting and interpreting disproportionality analyses derived from spontaneous reporting systems
2024 Standout
2 intermediate papers

Works of Lawrence Severt being referenced

Long‐Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52‐Week Extension Trial
2020
Neuroimaging Markers of Motor and Nonmotor Features of Parkinson's Disease: An [<sup>18</sup>F]Fluorodeoxyglucose Positron Emission Computed Tomography Study
2013

Author Peers

Author PMh PFM Neurology Physiology Last Decade Papers Cites
Lawrence Severt 560 389 255 261 35 869
Anne Zutavern 141 10 1 707 26 2.1k
L. D. B. Machado 4 25 436
Palamarneri Sivaraman Hariharan 1 3 28 1.1k
Soghra Fatima 14 45 12 155 19 775
Nicholas P. Machara 15 339

All Works

Loading papers...

Rankless by CCL
2026